Physician profile
Edward A Craft
NPI 1043504780
$7,362.90
in general payments reported to CMS, 2019-2025
32 companies · $2,296 in 2025
The $2,296 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $181 · 2021: $1,212 · 2022: $158 · 2023: $925 · 2024: $2,122 · 2025: $2,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,343.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,488.25 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,234.23 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $696.69 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $608.45 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $567.89 | 2021-2025 | |
| Novo Nordisk INC | $397.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $331.03 | 2019-2025 | Spravato |
| Merck Sharp & Dohme LLC | $224.61 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Astellas Pharma US INC | $183.17 | 2019-2025 | Veozah |
| Axsome Therapeutics, INC. | $142.77 | 2024-2025 | Auvelity, Sunosi |
| E.R. Squibb & Sons, L.L.C. | $129.70 | 2020-2025 | Camzyos, Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.00 | 2021-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceutical Holding Company LTD. | $122.47 | 2022 | |
| Exact Sciences Corporation | $121.59 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.45 | 2019-2025 | Jardiance |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $109.13 | 2024-2025 | Repatha, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $104.32 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $87.50 | 2025 | Caplyta |
| Abbott Laboratories | $83.81 | 2025 | Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $81.52 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $70.21 | 2021 | |
| Dexcom, INC. | $66.35 | 2024-2025 | Dexcom G6 Transmitter |
| Allergan, INC. | $49.64 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $36.24 | 2019 | |
| Amarin Pharma, INC. | $35.92 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $35.19 | 2024-2025 | Qelbree |
| Amneal Pharmaceuticals LLC | $26.92 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.31 | 2024 | Lifevest |
| Antares Pharma, INC. | $17.44 | 2019 | |
| Eisai INC. | $16.12 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.59 | 2021 | |
| Currax Pharmaceuticals LLC | $13.92 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Craft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.